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The etiologic agent of anthrax, Bacillus anthracis, is a grampositive, rod-shaped, spore-forming bacterium. The disease
primarily affects ungulate herbivores, occasionally affects carnivores, and less frequently affects humans (30). Anthrax is a
disease well documented throughout human history, with suggestive reports in the Bible and Sanskrit manuscripts (5). Koch,
Pasteur, and others revolutionized the field of microbiology
with their studies using B. anthracis as a model organism (27).
Though anthrax has not been eradicated, the development of
effective animal and human vaccines has reduced its importance for humans and animals in developed countries over the
last century. Recently, however, anthrax research has become
increasingly important due to this pathogen’s central role in
biological warfare and biological terrorism (14). The importance of the disease in humans has been underscored by the
bioterrorism events of October 2001 in the United States. Now
more than ever, there is a need for rapid, reliable, and highly
specific detection assays.
Identification and detection systems based on real-time
quantitative PCR (QPCR) have been described for several
bacteria, including B. anthracis (1, 2, 13, 22). These techniques
are easy to design, simple to carry out, and commonly applied
to monitor and detect the microbial status of sample specimens. With proper design and careful application, diagnostic
QPCR systems can be applied to reliably estimate and, in the
present study, absolutely enumerate target organisms as well as
nucleic acid elements, such as plasmids, within those organisms
(20).
The virulence of B. anthracis has been associated with two
megaplasmids, pXO1 and pXO2 (30). Plasmid pXO2 (60

MDa) carries the genes required for synthesis of an antiphagocytic poly-D-glutamic acid capsule facilitating host immune
system evasion (9, 16, 21, 31, 32, 35). The 110-MDa plasmid
pXO1 is required for synthesis of the three anthrax toxin proteins, edema factor (EF), lethal factor (LF), and protective
antigen (PA) (31). These proteins act in binary combinations
to produce the two anthrax toxins: edema toxin (PA and EF)
and lethal toxin (PA and LF) (17). Although the roles of the
capsule and toxin in disease pathogenesis have been well characterized, the copy numbers of these plasmids have not been
investigated (7, 18). A recently published study has alluded to
the copy number of each plasmid per cell of the Ames isolate
of B. anthracis (26). While differences have been observed in
the virulence of various isolates of B. anthracis, only a portion
of these differences can be attributed to plasmid-related effects
(35).
Previous studies have shown that the virulence of B. anthracis can differ among isolates or strains (6, 8, 19). Some variation in virulence can be related to the presence or absence of
the plasmids. Isolates lacking either the pX01 or pX02 plasmid
are considered either avirulent or significantly attenuated (23,
33). However, this does not explain the variation in virulence
observed in studies comparing fully virulent isolates such as the
Ames and Vollum 1B strains (11, 12). Explanations for these
differences in virulence have never been fully substantiated. In
a challenge study using guinea pigs vaccinated with the human
vaccine currently licensed in the United States, anthrax vaccine
adsorbed (AVA), 20 genetically diverse B. anthracis isolates, as
defined by multilocus variable-number tandem repeat analysis
(MLVA), yielded survival rates ranging from 0 to 100% (results presented below). Several possible mechanisms that may
be responsible for the modulation of virulence exist, including
the copy number of plasmids per cell and transcription regulation of the anthrax toxins and capsule, and additional varia-
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Bacillus anthracis is a bacterial pathogen of great importance, both historically and in the present. This study
presents data collected from several investigations and indicates that B. anthracis virulence is associated with
the clonality and virulence of plasmids pXO1 and pXO2. Guinea pigs vaccinated with Anthrax Vaccine
Adsorbed were challenged with 20 B. anthracis isolates representative of worldwide genetic diversity. These
same isolates were characterized with respect to plasmid copy number by using a novel method of quantitative
PCR developed for rapid and efficient detection of B. anthracis from environmental samples. We found that the
copy numbers for both pXO1 and pXO2 differed from those in previously published reports. By combining the
data on survival, plasmid copy numbers, and clonality, we developed a model predicting virulence. This model
was validated by using a randomly chosen set of 12 additional B. anthracis isolates. Results from this study will
be helpful in future efforts to elucidate the basis for variation in the virulence of this important pathogen.
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Isolate

Country or strain

Cluster

% Survival

No. of pXO1 (rpXO1)

No. of pXO2 (rpXO2)

Model isolate set
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

China
Australia
Namibia
Ames
Germany
Turkey
France
Turkey
Pakistan
South Africa
Zambia
Turkey
United States
South Africa
Argentina
Mozambique
Canada
United States
Pakistan
Vollum

A3b
A3a
A3a
A3b
A3a
A3a
B2
A1b
A2
B1
A3a
A1b
A3a
A3b
A3a
B1
A1a
A1a
A4
A4

0
0
19
38
25
31
31
38
38
44
44
44
44
50
50
75
69
69
75
94

185 (30.9)
121 (20.2)
242 (40.3)
65 (10.8)
113 (18.9)
131 (21.8)
243 (40.5)
236 (39.4)
120 (20.0)
66 (11.0)
242 (40.4)
172 (28.7)
109 (18.1)
212 (35.3)
104 (17.4)
95 (15.9)
24 (40.5)
128 (21.4)
191 (31.9)
69 (11.5)

9 (1.5)
32 (5.4)
5 (0.9)
2 (0.3)
5 (0.9)
11 (1.8)
4 (0.6)
27 (4.5)
1 (0.2)
2 (0.4)
15 (2.5)
6 (1.0)
4 (0.7)
16 (2.6)
7 (1.2)
1 (0.2)
18 (3.0)
5 (0.8)
14 (2.3)
10 (1.6)

Test isolate set
A
B
C
D
E
F
G
H
I
J
K
L

Indonesia
South Korea
United States
South Africa
India
United States
Mozambique
Norway
Croatia
Canada
United States
United States

A4
A3a
A3a
A4
A3a
A3b
B1
B1
B1
A1a
A1a
A1a

13
19
19
25
25
31
44
44
44
50
50
56

44.4 (7.4)
62 (10.4)
89 (14.8)
94 (15.6)
33 (5.5)
44 (7.3)
86 (14.4)
218 (36.3)
49 (8.2)
83 (13.9)
65 (10.8)
115 (19.2)

4 (0.6)
3 (0.5)
3 (0.5)
11 (1.9)
2 (0.4)
2 (0.4)
10 (1.6)
1 (0.2)
3 (0.5)
5 (0.9)
4 (0.7)
9 (1.5)

tion may be mediated by the generation time and germination
efficiency. These factors are likely to be associated with mutations that could be clonally heritable.
In this study, we show that B. anthracis virulence is related to
clonality and pXO1 and pXO2 copy number. We modeled the
percentage of survival of guinea pigs vaccinated with AVA and
challenged by 20 genetically diverse B. anthracis isolates as
defined by the MLVA. Absolute QPCR analysis was used to
determine the plasmid copy number present per cell (pXO1
and pXO2) for each of the isolates. Our model describing the
virulence of B. anthracis isolates in AVA-vaccinated guinea
pigs by using MLVA cluster association, clonality, and plasmid
copy number was then verified by using a randomly chosen
group of 12 isolates.
MATERIALS AND METHODS
Bacterial isolates. A total of 36 isolates of B. anthracis were included in this
study (Table 1). All of these isolates have been previously genotyped using
MLVA (14). Initially, 20 isolates were chosen for animal challenge studies and
plasmid copy number characterization based on their representation of genetic
diversity from a worldwide collection. Genetic diversity was determined by
MLVA cluster assignment and was based on genotypic allele patterns described
previously for eight variable-number tandem repeat loci (15). The isolates used
in this study are representative of all seven major MLVA clusters. An additional
12 isolates that were previously genetically characterized using MLVA for the

purpose of model validation were later chosen at random from the worldwide
collection.
DNA preparation. DNA from each isolate was obtained by heat lysis of a single
colony. The isolates were streaked onto blood agar plates and then incubated at
37°C overnight. A single colony from each plate was transferred into a 0.22
m-pore-size microcentrifuge tube containing 200 l of Tris-EDTA (Tris-HCl
[pH 8.0], 1.0 mM EDTA). The colony was resuspended by repetitive pipetting.
The cellular suspension was heated to 95°C for 20 min and then cooled to room
temperature. Cellular debris and any possible contamination by spores were
removed by centrifugation at 6,000 ⫻ g for 1 min. Centrifugation was conducted
inside a biosafety cabinet to contain any aerosols. The supernatant was then
transferred to a new tube for storage. One microliter of the lysate contained
sufficient template to support a single PCR.
Oligonucleotide design of probes and primers. The loci sequences used for the
QPCR assay primer and probe development on the chromosome and plasmids
pXO1 and pXO2 have previously been reported (25, 29). Probe and primer
sequences (Table 2) were designed with the Primer Express software program
(Perkin-Elmer Applied Biosystems, Foster City, Calif.) according to the manufacturer’s instructions. The sequence of the probe was selected based on previously described criteria: predicted cross-reactivity to B. anthracis, the melting
temperature of the probe at 69°C, lack of predicted dimer formation with corresponding primers and of self-annealing, a 10°C higher melting temperature of
the probe than of the primers, and no stretches of identical nucleotides longer
than four and no G at the 5⬘ end of the probe (10). The fluorescent reporter dye
at the 5⬘ end of the probe was 6-carboxy-fluorescein (FAM); the quencher at the
3⬘ end was 6-carboxy-tetramethyl-rhodamine (TAMRA).
Standards for absolute quantitation. The standards for absolute quantitation
of each primer and probe grouping (pXO1, pXO2, and BA813) were prepared
as follows. The PCR-amplified fragment obtained with the primers for each
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TABLE 1. B. anthracis isolates by country and cluster, the survival of AVA-vaccinated guinea pigs, and the calculated
number of plasmids pXO1 and pXO2
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TABLE 2. QPCR primers and probes
Primer

Amplicon
size (bp)

Sequence (5⬘-3⬘)

pXO1 plasmid (pagA)

BApXO1-PR
BApXO1-FP
BApXO1-RP

6FAM-TCGAATTACTAAATCCTGCAGATACACTCCCACC-TAMRA
AATGATCAATTGCGACCGTACTT
TGCATGCGTCGTTCTTTGATA

pXO2 plasmid (capA)

BApXO2-PR
BApXO2-FP
BApXO2-RP

6FAM-TACTGCTTCTGTACGTTGTACCCATGTCGC-TAMRA
TCACCAACCATCGTCATCGT
CGTTATGTAGCAATCGTATTACCTCTTAT

131

Chromosome

BA813-PR
BA813-FP
BA813-RP

6FAM-AATGCCAGGTTCTATACCGTATCAGCAAGCTATTC-TAMRA
GGAGGGAATACAGCAAACACAGA
TGCAACTGATGGGATTTCTTTCT

123

grouping was cloned by using pcDNA3.1/V5-His-TOPO TA and transformed
into Escherichia coli TOPO10 (Topo TA cloning kit; Invitrogen, NV Leek, The
Netherlands). Purification of the plasmid DNA was carried out with a commercial plasmid DNA isolation kit (Qiagen, Basel, Switzerland). The DNA concentration was determined with a spectrophotometer (Beckman DU-600; Beckman
Coulter, Inc., Fullerton, Calif.) and was diluted to 1010 templates/5 l. Dilutions
were made equivalent to 109, 107, 105, 103, 10, and 1 copy of template per 5 l.
For bidirectional DNA sequencing of the insert, the forward primer and reverse
primer were used. The nucleotide sequence was determined by using a fluorescence-based automated sequencing system (ABI 377A DNA sequencer) obtained from Microsynth, Balgach, Switzerland. The plasmid insert was sequenced
to confirm its identity with B. anthracis.
Test of detection limit for the QPCR assay. The detection limit of the QPCR
assays for B. anthracis was determined by making serial dilutions of overnight
cultures of two isolates, isolate 4 and isolate 17 (Table 1), suspended in 0.9%
NaCl. The suspension was adjusted to a density corresponding to that of a
McFarland 1.0 standard, and from this, serial dilutions were made. Plate counts
from each dilution were performed in triplicate on 5% sheep blood agar (Remel). A total of 200 l of culture from each dilution was heat lysed as described
above, and 5 l was used for the 5⬘ nuclease assay. Each test was repeated three
times.
Specificity of the QPCR assays. Ten isolates of closely related Bacillus spp.
were used to examine the specificity of the QPCR assay. These isolates were B.
cereus ATCC 4381 and ATCC 14579, B. subtilis ATCC 6051, B. megaterium
ATCC 14580, and four confirmed environmental isolates and two environmental
isolates of B. thuringiensis. The environmental isolates were confirmed by 16S
rRNA sequencing.
QPCR assay. Each 25-l PCR mixture contained 1⫻ TaqMan universal PCR
master mix (part number 4304437; Applied Biosystems), 16 M concentrations
of each primer, a 100 nM concentration of fluorogenic probe, and 5 l of
template or plasmid standard. DNA amplification was carried out in MicroAmp
optical 96-well reaction plates (part number N801-0560; Applied Biosystems)
sealed with MicroAmp optical caps (part number N801-0935; Applied Biosystems). The cycling program consisted of heating for 2 min at 50°C and then 10
min at 95°C followed by a two-stage temperature profile of 95°C for 15 s and 60°C
for 1 min, repeated for 40 cycles. Amplification, data acquisition, and data
analysis were carried out with an ABI 7700 sequence detector (Applied Biosystems). All QPCR tests were repeated at least three times for each of three
individual colonies from each isolate in the study.
Vaccination and challenge. Hartley guinea pigs (Charles River, Wilmington,
Mass.) were vaccinated intramuscularly (i.m.) at 0 and 4 weeks with 0.5 ml of
AVA (Bioport, Lansing, Mich.). At 10 weeks after the first vaccination, the
guinea pigs were challenged i.m. with 10,000 spores of virulent B. anthracis.
Survival was noted for 14 days postchallenge. The research described in this
report complied with all relevant federal guidelines and institutional policies and
adhered to the Guide for the Care and Use of Laboratory Animals as promulgated
by the Institute of Laboratory Animal Resources of the National Research
Council (24).
Absolute copy number of loci, statistical analysis, and modeling. All calculations of means, statistical analyses, and modeling were performed by using SPSS
software, version 10.2. The mean absolute copy number of chromosomal loci per
cell was determined by back calculation using the total number of cells in a series
of dilution trials analyzed with the QPCR assay. Cross-validation of the mean
number of plasmid loci per cell was performed using the same methodology. The
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mean number of cells per trial was determined by using most-probable-number
methods and was confirmed with direct spore counts. The ratios of plasmid
copies to chromosomal DNA copies were derived by first dividing the total
estimated copy number of chromosomal loci determined using the QPCR assay
by the mean absolute copy number of chromosomal loci per cell (determined as
described above) and then dividing the estimated total copy number of plasmid
loci (for each of the two plasmids individually) by the adjusted chromosomal
copy number.
After the data set had been assembled and the ratios of plasmid copies to
chromosome copies had been calculated, the means of the MLVA clusters were
estimated in conjunction with a one-way analysis of variance (ANOVA). The
percentage of survival of guinea pigs was modeled by using a univariate general
linear model. The dependent variable, percentage of survival, was modeled with
two covariates, ratio of pXO1 to chromosome (rpXO1) and ratio of pXO2 to
chromosome (rpXO2), and the factor MLVA cluster, which had seven levels
corresponding to the seven major MLVA clusters (16). The model examined the
main effects of the covariates and factor only. No interactions were examined for
the model. Parameter estimates and 95% confidence intervals were calculated
for each covariate, factor level, and model intercept term. Statistical significance
levels for evaluation of the model were set a priori at an alpha value of 0.05.
Post-hoc tests were conducted by using the Student-Newman-Keuls method.

RESULTS
Specificity and sensitivity of the 5ⴕ nuclease assay. The three
unique primer-probe sets designed for the specific identification and target quantification of B. anthracis correctly discriminated all isolates tested. The analytical sensitivity of the
QPCR assays was comparable to that of a previously described
nested PCR (3). The assay system resolution was sufficient to
detect one copy of the standard plasmid. The samples containing no template gave a negative result.
Chromosome, pXO1, and pXO2 loci per bacteria and plasmid ratios. The average number of chromosomal loci detected
per cell was approximately six for all of the isolates examined.
The number of loci detected per cell for each of the virulence
plasmids, however, varied greatly among the isolates, ranging
from 33 (isolate E) to 243 (isolates 7 and 17) for pXO1 and
from 1 (isolates 9, 16, and H) to 32 (isolate 2) for pXO2. The
plasmid/chromosome loci ratios for each isolate are listed in
Table 1.
The mean plasmid/chromosome loci ratios calculated over
the seven MLVA clusters were significantly different as indicated by the results of an ANOVA (P ⬍ 0.05) (Fig. 1). Posthoc tests indicated that there were three overlapping groups
for pXO1. Group 1 included MLVA clusters A2, A3a, A3b,
A4, and B1; group 2 included MLVA clusters A1, A2, A3a, and
A3b; and group 3 included MLVA clusters A1 and B2. Post-
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FIG. 1. Mean ratios of plasmids (pXO1 and pXO2) to chromosomes and percentage of survival of AVA-vaccinated guinea pigs by MLVA
clusters. There is a wide range of variability for all of the means across MLVA clusters, and it is difficult to detect any apparent associations between
mean plasmid ratios and percentage of survival. The dendrogram below the graph is adapted from previous published genetic typing results (15)
and indicates the genetic relationships among the MLVA clusters shown.

hoc tests indicated that there were two overlapping groups for
pXO2. Group 1 included MLVA clusters A2, A3a, A3b, A4,
B1, and B2, and group 2 included MLVA clusters A1, A3a,
A3b, B1, and B2.
Vaccination challenge and survival. The survival of the vaccinated guinea pigs ranged from 0 to 94%. The percentages of
survival of the vaccinated guinea pigs challenged with each of
the isolates used in this study are listed in Table 1. The overall
average survival was approximately 40%. The average time to
death was 5 days for all isolates tested and ranged from 3 to 7
days. The mean percentage of survival of guinea pigs for each
MLVA cluster is shown in Fig. 1. The results of an ANOVA
indicated that the means were different (P ⬍ 0.05). Post-hoc
testing showed four groups, two of which had overlapping
membership (Fig. 2). The most virulent MLVA cluster (cluster
A3b), indicated by lowest survival, had a mean survival of
21.3% and included an isolate of the Ames strain.
Model of virulence. We analyzed the combined data set of
percentage of survival, ratio of plasmid to chromosome
(rpXO1 and rpXO2), and MLVA cluster assignment by using
a general linear univariate model. The overall model statistics
indicated that rpXO1 was not a significant predictor of survival
(P ⬎ 0.05) but that rpXO2 and MLVA cluster were significant
(P ⬍ 0.05 for both). The parameter estimate obtained for
rpXO1 was not significant; however, the estimate obtained for
rpXO2 was significant (rpXO1 ⫽ 0.06, P ⬎ 0.05; rPXO2 ⫽
⫺1.93, P ⬍ 0.05). The magnitude of the parameter estimates

obtained for each of the seven MLVA clusters, ranging from
0.00 (A3b) to 75.41 (A4) (Fig. 2), indicates a much greater
influence on survival outcome than that observed with either
plasmid ratio. As previously mentioned, post-hoc testing re-

FIG. 2. MLVA cluster factor model of virulence parameter estimates and their 95% confidence intervals (C.I.), along with groupings
as indicated by post-hoc testing. MLVA cluster A3b was the arbitrarily
set referent factor level and therefore is set at 0. Groups 1 and 2 are
overlapping, indicating that there may be as few as three statistically
significant different virulence groups or as many as five.
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FIG. 3. Observed and predicted survival rates of AVA-vaccinated guinea pigs challenged with diverse B. anthracis isolates. Twenty isolates were
used to construct the model of virulence (A), and a set of 12 isolates was then used to validate the model (B). While there is some deviation
between the predicted and observed percentages of survival of guinea pigs when an MLVA cluster factor and plasmid ratio covariates were used,
the model is surprisingly robust in performance.

vealed two overlapping and two distinct statistical groups (Fig.
2), indicating that there are potentially as many as five or as
few as three separate groups among the MLVA clusters.
Graphs of the observed and predicted percentages of survival
for both of the isolates with which the model was constructed
and a test set of 12 randomly chosen isolates indicate a good
model fit (Fig. 3).
Figures 1 and 2 show a grouping of the MLVA clusters into
three overlapping groups. The least virulent group, A4, contains isolates from the United States, Norway, Europe, and
Asia (15). This group also contains the Vollum strain, which
was used in the United Kingdom biological warfare program
(14). The middle group is made up of clusters A1 and B1 and
is of medium virulence. Clusters A1 and B1 are similar in
virulence but are geographically diverse. Isolates in the A1
cluster were found predominantly in the region stretching from
Wood Bison National Park in Canada south to Texas in the
United States. Southern African isolates make up the majority
of the B1 cluster (15). The most virulent group consists of four
clusters, A2, A3a, A3b, and B2. This group is also geographically diverse. B2 has been found almost exclusively in southern
Africa (15). A3a is associated with isolates from around the
world, especially Turkey and Namibia. A3b is dominated by
isolates from China, yet this cluster also contains the Ames
strain.

DISCUSSION
In this study, we present results demonstrating that B. anthracis virulence is related to clonality (as indicated by MLVA
genotype cluster) and pXO1 and pXO2 copy number. By combining data collected from challenge studies of AVA-vaccinated guinea pigs and data concerning pXO1 and pXO2 plasmid copy number from a genetically diverse set of isolates, we
developed a model that is predictive of virulence. We then
used this model to compare the predicted and observed survival rates of AVA-vaccinated guinea pigs when challenged
with a randomly chosen set of isolates. It is likely that factors
affecting the variation in virulence we observed are due to
mutations that are heritable and clonally passed on to daughter
cells. This could also include a predisposition for stable plasmid copy number configurations of pXO1 and pXO2.
While we can offer no explanation for the association of
higher or lower levels of virulence with specific MLVA clusters, the relationship is plausible from the standpoint of mutations and clonality. Other examples of genetic typing-based
group differences in pathogen virulence have been observed
(4). Further investigation to determine the underlying reasons
for variation in virulence should center on the genetic differences between representative isolates from different MLVA
clusters, such as A3b and A4, that showed extreme differences
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in mean survival and model parameter estimates. Although
rpXO2 was found to be a significant contributor in the virulence model, there was no distinct difference in the numbers of
plasmids per cell for clusters A3b and A4; therefore, we can
conclude that the differences in the observed virulence were
due to factors other than the number of plasmids per cell.
Our observations have revealed tremendous variation in
pXO1 and pXO2 copy numbers per cell by using a genetically
diverse collection of isolates. These observations were made
possible by the use of a new method for molecular detection of
B. anthracis, QPCR. Using QPCR, we were able to detect one
copy of the standard plasmids for the chromosome, pXO1, and
pXO2. A common belief in the research community has been
that B. anthracis contains only one copy of each plasmid. Here,
using a QPCR method, we have shown that there is more than
one copy of each plasmid per cell and that there is tremendous
variation among genetically diverse isolates. Our results indicate that there may be as many as 243 copies of pXO1 and 32
copies of pXO2 per cell. The apparent disparity between our
results for the plasmid copy number-to-chromosome ratio and
those of Read et al. may be due to a difference in the growth
phase when the DNA was harvested (Timothy Read, personal
communication). While the difference may seem extreme, it
could be appropriate from a biochemical and virulence viewpoint.
It has long been known that different isolates exhibit different levels of virulence (11, 19, 28). The factors responsible for
the different levels of virulence in these isolates are unknown.
We have shown that the number of pXO2 plasmids in each
bacterial cell contributes to the level of virulence associated
with that isolate (Fig. 4). Although the model that we developed indicated that pXO1 copy number does not contribute
significantly to virulence, it is likely that in an experimental
challenge of unvaccinated animals, one would find that the

number of copies of pXO1 would also contribute to variations
in virulence. However, the results of the present study indicate
that pXO2 plays a significant role in virulence and can contribute to observed variation in virulence. An alternative interpretation for our results would be that the variation in the
percentages of survival of guinea pigs represents differences in
the ability of genetically diverse isolates to overcome immunity
conferred by the AVA vaccine. This seems unlikely when we
consider that the basis for protection and immunity is the
antibodies formed to block the PA produced by pXO1. Furthermore, pXO2⫺ strains are considered avirulent (or at least
severely reduced) and injection into animals confers immunity.
Indeed, this is the basis of livestock vaccines for protection
against anthrax. In the mouse model, isolates that contain
pXO2 only remained lethal at low doses (34). Welkos showed
that the pXO2 plasmid contributes significantly to the virulence of the organism (33) and that mutants producing greater
amounts of capsule exhibited a higher level of virulence than
did the parental strain. Figure 4 shows an increasing gradation
of virulence associated with an increase of pXO2.
Virulence studies of anthrax are an important source of
information, especially given the use of the organisms as an
agent of bioterrorism and/or biowarfare. This study has put
forward some interesting and significant information concerning the virulence of different isolates of B. anthracis and the
testing of these same isolates in an animal system. Trends in
the data with respect to plasmid copy number have revealed
clues that will take us into the next paradigm of virulence
testing. Hypotheses have been suggested that can now be
tested because of technological advances in molecular biology
techniques. Additional animal studies using unimmunized animals utilizing more representative isolates of all clusters are
recommended to validate the model and the cluster effect
observed in this study. Furthermore, validation of the model
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FIG. 4. Effect of pXO2/chromosome ratio on the percentage of survival across MLVA clusters. Each of the parallel lines shown represents
virulence model performance (percentage of survival) for each MLVA cluster while rpXO1 was held constant and rpXO2 varied over the range
observed. The figure dramatically illustrates the difference between the predicted percentages of survival for each MLVA cluster, as well as the
more subtle effect of additional copies of pXO2 plasmids, which are not otherwise observable.
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could lead to its use as a screening tool and complement the
testing of vaccine efficacy.
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